



Aerie Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Tuesday, May 8, 2018

April 26, 2018

DURHAM, N.C.--(BUSINESS WIRE)--Apr. 26, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its first quarter 2018 financial results will be released after the market closes on Tuesday, May 8, 2018. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company's financial results and provide a general business update.

The live webcast and a replay may be accessed by visiting the Company's website at <http://investors.aeriepharma.com>. Please connect to the Company's website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (888) 734-0328 (U.S.) or (678) 894-3054 (international) to listen to the live conference call. The conference ID number for the live call is 3992508. Please dial in approximately 10 minutes prior to the call. Telephone replay will be available approximately two hours after the call. To access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406 (international). The conference ID number for the replay is 3992508. The telephone replay will be available until May 15, 2018.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye. Aerie's first product, Rhopressa[®] (netarsudil ophthalmic solution) 0.02%, for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was approved by the U.S. Food and Drug Administration (FDA) in December 2017. A link to the full product label is available on the Aerie website at <http://investors.aeriepharma.com>. Aerie's second product candidate, Roclatan[™] (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of Rhopressa[®] and widely prescribed PGA latanoprost, achieved its primary efficacy endpoint in two Phase 3 registration trials, named Mercury 1 and Mercury 2, and also achieved successful 12-month safety and efficacy results in Mercury 1. The Roclatan[™] NDA submission is expected to take place in the second quarter of 2018. Aerie is also focused on global expansion and the development of additional product candidates and technologies in ophthalmology.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180426005023/en/>

Source: Aerie Pharmaceuticals, Inc.

Aerie Pharmaceuticals

Media:

Tad Heitmann, 949-526-8747

theitmann@aeriepharma.com

or

Investors:

Richard Rubino, 908-947-3540

rrubino@aeriepharma.com

or

Burns McClellan, Inc., on behalf of Aerie Pharmaceuticals

Media:

Justin Jackson, 212-213-0006

jjackson@burnsmc.com

or

Investors:

Ami Bavishi, 212-213-0006

abavishi@burnsmc.com